Patents by Inventor Susanne Nedergaard Grell

Susanne Nedergaard Grell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 11858992
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: January 2, 2024
    Assignee: NOVO NORDISK A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • METHODS OF TREATING AUTOIMMUNE DISEASE OR CHRONIC INFLAMMATION WITH ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20210253697
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: February 1, 2021
    Publication date: August 19, 2021
    Inventors: Vibeke Westphal STENNICKE, Christine Brender READ, Susanne Nedergaard GRELL, Charlotte WIBERG, Rune SALBO, Anette HENRIKSEN, Soeren PADKJAER
  • Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 10906975
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: February 2, 2021
    Assignee: NOVO NORDISK A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20190194321
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: December 4, 2018
    Publication date: June 27, 2019
    Applicant: Novo Nordisk A/S
    Inventors: Vibeke Westphal STENNICKE, Christine Brender READ, Susanne Nedergaard GRELL, Charlotte WIBERG, Rune SALBO, Anette HENRIKSEN, Soeren PADKJAER
  • Targeting tissue factor to activated platelets
    Publication number: 20190062429
    Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
    Type: Application
    Filed: September 13, 2018
    Publication date: February 28, 2019
    Inventors: Ida Hilden, Lars Christian Petersen, Jens Breinholt, Mette Dahl Andersen, Jais Rose Bjelke, Thomas Egebjerg, Jes Thorn Clausen, Susanne Nedergaard Grell
  • Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 10189904
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: January 29, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Targeting tissue factor to activated platelets
    Patent number: 10106606
    Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: October 23, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Lars Christian Petersen, Jens Breinholt, Mette Dahl Andersen, Jais Rose Bjelke, Thomas Egebjerg, Jes Thorn Clausen, Susanne Nedergaard Grell
  • ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20180105590
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: December 8, 2016
    Publication date: April 19, 2018
    Inventors: Vibeke Westphal STENNICKE, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune SaIbo, Anette Henriksen, Soeren Padkjaer
  • Antagonistic DR3 Ligands
    Publication number: 20170305994
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: July 5, 2017
    Publication date: October 26, 2017
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Antagonistic DR3 ligands
    Patent number: 9737612
    Abstract: The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: August 22, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Albrecht Gruhler, Susanne Nedergaard Grell, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Antagonistic DR3 ligands
    Patent number: 9713644
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: July 25, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20170190775
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: December 8, 2016
    Publication date: July 6, 2017
    Inventors: Vibeke Westphal STENNICKE, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune SaIbo, Anette Henriksen, Soeren Padkjaer
  • Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 9550830
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: January 24, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Antibodies that Bind and Block Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1)
    Publication number: 20150274825
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: February 26, 2015
    Publication date: October 1, 2015
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 9000127
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: April 7, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • ANTAGONISTIC DR3 LIGANDS
    Publication number: 20140294853
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: May 1, 2014
    Publication date: October 2, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Antagonistic DR3 ligands
    Patent number: 8765130
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: July 1, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • ANTAGONISTIC DR3 LIGANDS
    Publication number: 20130336984
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: August 23, 2013
    Publication date: December 19, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • ANTAGONISTIC DR3 LIGANDS
    Publication number: 20130330360
    Abstract: The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: March 1, 2012
    Publication date: December 12, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Albrecht Gruhler, Susanne Nedergaard Grell, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20130309239
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: July 30, 2013
    Publication date: November 21, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer